The Australian Research Data Commons (ARDC) invites you to participate in a short survey about your
interaction with the ARDC and use of our national research infrastructure and services. The survey will take
approximately 5 minutes and is anonymous. It’s open to anyone who uses our digital research infrastructure
services including Reasearch Link Australia.
We will use the information you provide to improve the national research infrastructure and services we
deliver and to report on user satisfaction to the Australian Government’s National Collaborative Research
Infrastructure Strategy (NCRIS) program.
Please take a few minutes to provide your input. The survey closes COB Friday 29 May 2026.
Complete the 5 min survey now by clicking on the link below.
Breathing Control As A Treatment For Non-Epileptic Seizures
Funder
National Health and Medical Research Council
Funding Amount
$1,740,186.00
Summary
Non-epileptic Seizures (NES) are fits that look like epilepsy but are not, and are instead thought to be a psychological response to problems. Treating them psychologically is difficult, however, and doesn't usually work. We have discovered that patients' fits involve hyperventilation, like a panic attack, and can be stopped by teaching them to control their breathing in a similar way. In this study we aim to prove this, by completing a trial of breath control training in NES.
'Azithromycin Before Birth'- Single Dose Azithromycin Shortly Before Birth To Reduce Infection In Aboriginal Mothers And Babies: A Randomised Controlled Trial.
Funder
National Health and Medical Research Council
Funding Amount
$3,205,108.00
Summary
Aboriginal mothers and babies in the Northern Territory have high rates of infection. A single dose of azithromycin given during labour (or prior to caesarean section) may reduce the rates of subsequent bacterial infection. This pragmatic clinical trial ('Azithromycin before Birth') will assess a simple intervention that has the potential to substantially improve health outcomes for women and babies at risk of new bacterial infection after birth.
IMPLORE - Implementing An Opioid Stewardship Intervention To Reduce Opioid Use
Funder
National Health and Medical Research Council
Funding Amount
$2,352,236.00
Summary
Back pain is the leading cause for opioid use globally. Guidelines actively discourage opioid use for this condition but unfortunately it commonly ends up managed with opioid medicines. Urgent efforts are needed to reduce the burden of harm associated with excessive prescribing of opioids for back pain. This trial will evaluate a clinical care model that is grounded in research, and designed to curb opioid analgesic use and achieve better health outcomes for people with back pain.
AGITG TOP GEAR: A Randomised Phase II/III Trial Of Preoperative Chemoradiotherapy Versus Preoperative Chemotherapy For Resectable Gastric Cancer
Funder
National Health and Medical Research Council
Funding Amount
$621,644.00
Summary
While surgery to remove stomach cancer has been traditionally accepted as the only way to potentially cure the disease, there have been several recent advances using chemotherapy and/or radiotherapy both before and after surgery. Doctors' opinions remain divided regarding best treatments to give and in what order. This trial will address the important question of whether combined chemotherapy plus radiotherapy is more effective than chemotherapy alone in improving cure rates for stomach cancer.
A Phase III Randomised Placebo-controlled Trial Of Mirtazapine As A Pharmacotherapy For Methamphetamine (Ice) Dependence
Funder
National Health and Medical Research Council
Funding Amount
$3,923,009.00
Summary
Crystalline methamphetamine ('ice') is a growing concern in Australia. There are no approved medications that can be used to treat dependence on this drug. This clinical trial will examine whether mirtazapine, a newly identified treatment agent for methamphetamine use, can be used safely and effectively in routine clinical care to manage methamphetamine dependence in Australia.
The Effect Of High SPF Sunscreen Application On Vitamin D
Funder
National Health and Medical Research Council
Funding Amount
$1,175,123.00
Summary
Sunscreen prevents sunburn and skin cancer, and current guidelines are that it should be routinely used when the maximum UV index is forecast to reach at least 3. However, applying sunscreen in laboratory experiments reduces vitamin D production, and there is concern that regular application of high SPF sunscreens might increase the risk of vitamin D deficiency. We propose a randomised controlled trial to determine if adhering to the current guidelines decreases vitamin D.
A Randomised Trial Of The Effects Of SGLT2 Inhibition Versus Metformin On Decline In Renal Function When Used As First Line Therapy In Type 2 Diabetes
Funder
National Health and Medical Research Council
Funding Amount
$3,815,692.00
Summary
Type 2 diabetes affects 5 in 100 Australians with many going on to develop serious heart and kidney complications. Sodium glucose co-transporter 2 (SGLT2) inhibitors are a new type of medicine that may provide benefit when used early in diabetes, but that are currently only used once complications have developed. This study will test the value of SGLT2 inhibitor treatment for kidney protection in Australians with newly diagnosed type 2 diabetes.
Intermittent Preventive Treatment In Pregnancy With Sulphadoxine-pyrimethamine Plus Dihydroartemisinin-piperaquine To Reduce Adverse Pregnancy Outcomes And Prevent Malaria In Papua New Guinea: A Randomised Controlled Trial
Funder
National Health and Medical Research Council
Funding Amount
$2,938,453.00
Summary
Millions of pregnancies are complicated by malaria worldwide. Monthly sulphadoxine-pyrimethamine (SP) treatments, the current treatment strategy, no longer protects from malaria but improves birth outcomes through non-malarial effects. Dihydroartemisinin-piperaquine clears malaria but babies are smaller compared to women who received SP. A clinical trial of their combination has potential to substantially improve health outcomes for women and babies in Papua New Guinea and beyond.
Preventing Infections In Patients With Blood Cancer Through Evidence-based Use Of Immunoglobulin Or Alternatives: The RATIONALISE Trial
Funder
National Health and Medical Research Council
Funding Amount
$2,490,421.00
Summary
Patients with blood cancers, with immune deficiency from low antibody levels and other disease or treatment factors, are at risk of life-threatening infection. Immunoglobulins (Ig) made from plasma can supplement antibody levels. Government criteria recommend stopping Ig therapy in stable patients, but with no evidence for when or how to do so. RATIONALISE will provide this evidence, to improve patient outcomes, reduce risks and costs, and make better use of blood products for the community.
Reducing Household Air Pollution Exposure To Improve Early Child Health And Development; Extending The Intervention And Follow-up Of Poriborton: The CHANge Trial.
Funder
National Health and Medical Research Council
Funding Amount
$2,916,420.00
Summary
Around the world each year household air pollution causes 4.3 million deaths. Mothers, babies and children, who spend the most time at home are extremely vulnerable. We will study the health of infants who have had reduced exposure in their first critical years of life and compare them to infants whose exposure was not reduced. This will provide compelling evidence for governments around the world of the need to assist families in developing settings to adopt clean energy.